Hydrodissection technique for liver lesions near the duodenum
Hydrodissection of the Hepatoduodenal Ligament
This study is testing a new technique to safely treat liver lesions near the duodenum to see if it can reduce the risk of damage to the duodenum during the procedure.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 13 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Strasbourg, France Academic / other |
| Locations | 1 site (Strasbourg) |
| Trial ID | NCT06190821 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the feasibility of hydrodissection of the hepatoduodenal ligament during percutaneous treatment of liver lesions that are adjacent to the duodenum. The goal is to minimize the risk of thermal injury to the duodenum, which can limit the effectiveness of lesion removal and impact oncologic outcomes. The study will analyze data from patients who underwent this procedure at the University Hospital in Strasbourg between January 2019 and July 2022.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who have undergone percutaneous ablation of liver lesions requiring hepatoduodenal ligament hydrodissection.
Not a fit: Patients who oppose the reuse of their data for research purposes will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could improve the safety and effectiveness of treating liver lesions located near the duodenum.
How similar studies have performed: While this specific approach is novel, similar studies have explored techniques to minimize injury during liver procedures, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria: * Major subject (≥18 years of age) * Subject who underwent percutaneous ablation of primary or secondary liver lesions at HUS that required per-procedure hepatoduodenal ligament hydrodissection in the interventional imaging department of the New Civil Hospital from January 2019 to July 2022. * Subject who has not expressed opposition to the reuse of their data for the purpose of this research. Exclusion Criteria: - Opposition to the reuse of his/her data for the purpose of scientific research.
Where this trial is running
Strasbourg
- Service Imagerie interventionnelle oncologique et viscérale - CHU de Strasbourg - France — Strasbourg, France (Recruiting)
Study contacts
- Study coordinator: Julien GARNON, MD
- Email: julien.garnon@chru-strasbourg.fr
- Phone: 33 3.69.55.03.04
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.